Policies have been introduced intensively, and a large number of pharmaceutical companies have vigorously focused on innovative traditional Chinese medicine drugs

[Pharmaceutical Network Industry News] Traditional Chinese medicine is the cornerstone of the development of traditional Chinese medicine.
It is reported that at present, China's traditional Chinese medicine review and approval work is generally improving.

.

And many traditional Chinese medicine companies said that they will promote the research and development of innovative traditional Chinese medicine
.

Among them, Fangsheng Pharmaceutical stated in this year's semi-annual report that it is committed to building a health industry group with innovative traditional Chinese medicine as its core, and driving the continuous improvement of the company's core competitiveness with "innovative traditional Chinese medicine research and development" and "management reform"
.

It also has a deep accumulation in the research and development of innovative traditional Chinese medicines
.

It is reported that in the first half of this year, its self-developed traditional Chinese medicine innovative drug Xiaoer Jingxing Zhike Granules obtained the "Approval Notice for Supplementary Application for Drug Clinical Trials" issued by the State Food and Drug Administration, and is used for adults with acute tracheo-bronchitis (wind-cold and heat syndrome) exploratory clinical trials; Nuolitong Granules obtained the Phase III clinical study summary report, and submitted the project registration to the State Food and Drug Administration
.

Weikang Pharmaceutical also stated that since its establishment, the company has always adhered to the strategy of “establishing an enterprise through innovation and strengthening the enterprise through technology”, adhered to the market-oriented orientation, and continued to innovate and iterate on technologies and products, so as to empower the sustainable development of the enterprise
.

In terms of key research and development projects, the research projects include 2 class 1.
1 innovative traditional Chinese medicine drugs (Shendan Tongnao Dropping Pill, Huangjia Ruangan Granule), 2 class 2 improved new drugs (Yinhuang Inhalation Solution, Yinhuang Drop) Pills), 8 classic recipes (Wenjing Tang, Jichuanjian, Yangwei Decoction, Sanjia Fumai Decoction, Erdong Decoction, Wuwei Disinfection Drink, Kaixin Powder, Jinshui Liujun Decoction)
.

Yiling Pharmaceutical has always adhered to the innovation and development strategy driven by technology, and has formed an advantageous scientific and technological core competitiveness in which the theory of collateral disease guides the treatment of major clinical diseases and respiratory infectious diseases, and the innovation of the theory of collateral disease drives the research and development of new drugs
.

At present, the company's Qihuangmingmu capsules for the treatment of diabetic retinopathy are applying for new drugs, Luobitong tablets for the treatment of rheumatoid arthritis, Chaihuanglidan capsules for the treatment of chronic cholecystitis, and Yuping Tongqiao tablets for the treatment of allergic rhinitis have completed the new drug II.
Phase III clinical research is underway; Xiaoer Lianhua Qinggan Granules for treating common cold in children have completed Phase II clinical trials; Chaiqin Tonglin Tablets have been approved for clinical trials of new indications for "recurrent urinary tract infections" notice
.

 　　It is understood that the traditional Chinese medicine industry, as an industry related to the national economy and people's livelihood, has a strong rigid demand
.

In recent years, China has attached great importance to the inheritance, innovation and development of traditional Chinese medicine, and has intensively issued policies and measures to support the development of traditional Chinese medicine
.

 　　Among them, in the first half of 2022, a number of national supportive policies were intensively introduced
.

For example, in March 2022, the “14th Five-Year Plan for the Development of Traditional Chinese Medicine” was issued, proposing the development goals of traditional Chinese medicine during the “14th Five-Year Plan”; )" "Guidelines for Communication and Exchange Based on the "Three Combinations" Registration Review Evidence System (Trial)" was released, emphasizing the role of human experience in the inheritance and innovation of traditional Chinese medicine, so as to improve the success rate of research and development of new traditional Chinese medicines; May 2022 The "Key Tasks for Deepening the Reform of the Medical and Health System in 2022" was issued, which listed the promotion of the revitalization and development of traditional Chinese medicine as one of the key tasks, carried out medical, medical insurance, and pharmaceutical linkages to promote the inheritance, innovation and development of traditional Chinese medicine.
Medical service capacity building, etc.
; in June 2022, the "Opinions on Strengthening the Work of Traditional Chinese Medicine Talents in the New Era" was released, which is the first policy document in China to systematically deploy the work of traditional Chinese medicine talents in the new era, and the document is in the key areas of traditional Chinese medicine.
Requirements are put forward in terms of talent team building, traditional Chinese medicine education reform, and talent development system and mechanism reform
.

 　　According to the industry, the introduction of these policies has further demonstrated the state's high recognition of traditional Chinese medicine and provided strong momentum for the development of the traditional Chinese medicine industry
.

 For future development, companies have also expressed that they will promote the inheritance, innovation and development of traditional Chinese medicine.

.

 　　For example, Weikang Pharmaceutical said that looking forward to the future, relevant policies to encourage and support the development of traditional Chinese medicine will continue to be introduced, and the traditional Chinese medicine industry will face unprecedented development opportunities
.

Weikang Pharmaceuticals will continue to maintain and develop its own advantages, promote the inheritance, innovation and development of traditional Chinese medicine, and empower and enhance the high-quality development of the enterprise
.

Fangsheng Pharmaceutical also stated that it will continue to promote the optimization and adjustment of non-core businesses and better focus on the core business of innovative traditional Chinese medicine
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.